1.上海中医药大学附属曙光医院(上海 201203)
许嘉慧,女,硕士研究生,主要从事中医药治疗内分泌相关疾病的临床与基础研究工作
陆灏,主任医师,博士研究生导师; E-mail:luhao403@163.com
扫 描 看 全 文
许嘉慧,陈清光,韩煦等.基于文本挖掘和生物信息法探讨高催乳素血症中医组方用药规律及核心处方作用机制[J].上海中医药杂志,2022,56(02):10-17.
XU Jiahui,CHEN Qingguang,HAN Xu,et al.Study on the medication rules of traditional Chinese medicine prescription and the mechanism of core prescription for hyperprolactinemia based on text mining and bioinformatics methods[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(02):10-17.
许嘉慧,陈清光,韩煦等.基于文本挖掘和生物信息法探讨高催乳素血症中医组方用药规律及核心处方作用机制[J].上海中医药杂志,2022,56(02):10-17. DOI: 10.16305/j.1007-1334.2022.2005003.
XU Jiahui,CHEN Qingguang,HAN Xu,et al.Study on the medication rules of traditional Chinese medicine prescription and the mechanism of core prescription for hyperprolactinemia based on text mining and bioinformatics methods[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(02):10-17. DOI: 10.16305/j.1007-1334.2022.2005003.
目的,2,基于文本挖掘和生物信息法探讨高催乳素血症(HPRL)的中医组方用药规律,提取核心组方,初步探寻相关作用机制,指导临床治疗。,方法,2,检索中国知网(CNKI)、万方数据库(WanFang)及中文科技期刊全文数据库(VIP)中关于HPRL治疗的中医验案及临床研究文献,采用中医传承辅助平台分析 HPRL中医证候分布、药物性味归经、用药及剂量规律、组方特点,挖掘核心药物及处方;运用生物信息法分析核心处方的有效作用靶点及作用机制。,结果,2,筛选并录入处方完备的病案75个、相关方剂75首,涉及中药147种。HPRL中医证候以肝郁肾虚证为主,用药性偏温、平,味偏甘、苦、辛,主要归肝、脾、肾经,其中生麦芽治疗HPRL用量以60 g多见,高频药物包括白芍、当归、柴胡、生麦芽、茯苓、甘草等,得到相关药组40组;提取的核心处方以逍遥散化裁,可通过28个靶蛋白发挥治疗HPRL作用,共涉及928种生物学过程及36条信号通路,关键治疗作用与PI3K-Akt信号通路、JAK-STAT信号通路、 VEGF信号通路、Th17细胞分化信号通路、多巴胺能神经突触传导通路等密切相关。,结论,2,中医治疗HPRL多以疏肝健脾补肾、三脏同调为法,用药偏甘温调和,核心处方以逍遥散为基础,生物信息法分析显示核心处方药物均可作用于HPRL,对中医治疗HPRL具有潜在指导价值。
Objective,2,To explore the medication rules of traditional Chinese medicine (TCM) prescriptions for hyperprolactinemia (HPRL), extract the core prescriptions, and preliminarily seek the relevant mechanisms based on text mining and bioinformatics methods, in order to guide the clinical treatment.,Methods,2,The literatures of TCM cases and clinical research on the treatment of HPRL were searched from China National Knowledge Infrastructure (CNKI), WanFang Database (WangFang) and VIP Database (VIP). The TCM syndrome types of HPRL, the nature, flavor and channel tropism of medicines, the rules of prescription and dosage and the prescription characteristics were analyzed, and the core herbs and prescriptions were mined through TCM Inheritance Auxiliary Platform. The effective targets and mechanisms of core prescriptions were analyzed by bioinformatics methods.,Results,2,A total of 75 cases with complete prescriptions were screened and input involving 75 relevant prescriptions and 147 Chinese medicinal herbs. The main TCM syndrome of HPRL was liver stagnation and kidney deficiency syndrome, the nature and flavor of the Chinese medicinal herbs were mostly warm, flat, sweet, bitter and spicy, and the Chinese medicinal herbs mainly belonged to the liver, spleen and kidney channels. The dosage of raw barley germinating fruit in treating HPRL was mostly 60 g. The high-frequency Chinese medicinal herbs included root of common peony, root of Chinese angelica, root of Chinese thorowax, raw barley germinating fruit, Indian bread, root of ural licorice and so on, and 40 relevant herb groups were obtained. The extracted core prescription was modified Xiaoyaosan Decoction, and could be used to treat HPRL through 28 target proteins involving 928 biological processes and 36 signaling pathways. The key therapeutic effects were closely related to the PI3K-Akt signaling pathway, JAK-STAT signaling pathway, VEGF signaling pathway, Th17 cell differentiation signaling pathway, and dopaminergic neurosynaptic conduction pathway.,Conclusion,2,The therapeutic method of TCM on HPRL is mainly soothing liver, strengthening spleen and nourishing kidney, which could be summarized as the regulation of three internal organs. The nature and flavour of herbs is sweet, warm and mild. The core prescription is based on Xiaoyaosan Decoction, and the analysis of bioinformatics method shows that each herb in the core prescription can effectively act on HPRL, which has potential guidance value for TCM in treating HPRL.
高催乳素血症乳泣逍遥散文本挖掘中药研究生物信息
hyperprolactinemialactorrheaXiaoyaosan Decoctiontext miningtraditional Chinese herbal medicine researchbiological information
庞保珍,庞清洋,庞慧卿,等. 中医药治疗高催乳素血症不孕的研究进展[J]. 中国性科学,2010, 19(1): 22-24.
卢恒,梁卓. 高泌乳血症的中医药研究进展[J]. 中医临床研究,2017, 9(22): 147-148.
乐杰. 妇产科学[M]. 7版. 北京: 人民卫生出版社,2008: 107-108.
李健,卢朋,唐仕欢,等. 基于中医传承辅助系统的治疗肺痈方剂组方规律分析[J]. 中国实验方剂学杂志,2012, 18(2): 254-257.
郭润竹,王雄,马莉,等. 大麦芽碱对高催乳素血症大鼠泌乳素分泌的抑制作用[J]. 中成药,2018, 40(11): 2386-2389.
屈小会,张淑林,张鲜芳,等. 谈中医药治疗高催乳素血症[J]. 现代中医药,2018, 38(4): 84-86.
李兰,杨柳. 小议《本草经疏》之牛膝“性善下行”[J]. 中医药学报,2015, 43(5): 124-125.
HU Y, XIN H L, ZHANG Q Y, et al. Anti-nociceptive and anti-hyperprolactinemia activities of Fructus Viticis and its effective fractions and chemical constituents[J]. Phytomedicine, 2007, 14(10): 668-674.
LIU X, KANO M, ARAKI T, et al. ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice[J]. Endocrinology, 2015, 156(1): 71-79.
CORLAN A S, CIMPEAN A M, MELNIC E, et al. VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas[J]. Eur J Histochem, 2019, 63(1): 3010.
MCAVENEY K M, BOOK M L, LING P, et al. Association of 2',5'-oligoadenylate synthetase with the prolactin (PRL) receptor: alteration in PRL-inducible stat1 (signal transducer and activator of transcription 1) signaling to the IRF-1 (interferon-regulatory factor 1) promoter[J]. Mol Endocrinol, 2000, 14(2): 295-306.
倪丽莉,朱依敏. 雌激素诱导泌乳素瘤的研究进展[J]. 国际生殖健康/计划生育杂志,2009, 28(5): 327-330.
DO A V, CARVALHO K C, MACIEL G A, et al. The progesterone and estrogen modify the uterine prolactin and prolactin receptor expression of hyperprolactinemic mice[J]. Gynecol Endocrinol, 2015, 31(2): 148-151.
O'HARA L, CURLEY M, FERREIRA M T, et al. Pituitary androgen receptor signalling regulates prolactin but not gonadotrophins in the male mouse[J]. PLoS One, 2015, 10(3): e121657.
田沁森,李国亮,葛鹏飞. 泌乳素瘤发病机制的研究进展[J]. 中国妇幼保健,2018, 33(9): 2155-2158.
PASCUAL-MATHEY L I, ROJAS-DURAN F, ARANDA-ABREU G E, et al. Effect of hyperprolactinemia on PRL-receptor expression and activation of Stat and Mapk cell signaling in the prostate of long-term sexually-active rats[J]. Physiol Behav, 2016(157): 170-177.
GORVIN C M. The prolactin receptor: Diverse and emerging roles in pathophysiology[J]. J Clin Transl Endocrinol, 2015, 2(3): 85-91.
陈蓉蓉. mTOR,雌激素诱导大鼠泌乳素瘤的新治疗靶点[D]. 北京:北京协和医学院,2009: 1-74.
DWORAKOWSKA D, WLODEK E, LEONTIOU C A, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors[J]. Endocr Relat Cancer, 2009, 16(4): 1329-1338.
ONOFRI C, THEODOROPOULOU M, LOSA M, et al. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours[J]. J Endocrinol, 2006, 191(1): 249-261.
孟庆军,孟磊,金保哲,等. PRL腺瘤患者外周血Th17含量及IL-17表达与PRL水平的关系[J]. 中国实用神经疾病杂志,2016, 19(24): 12-14.
CAPOZZI A, SCAMBIA G, PONTECORVI A, et al. Hyperprolac-tinemia: pathophysiology and therapeutic approach[J]. Gynecol Endocrinol, 2015, 31(7): 506-510.
0
浏览量
337
下载量
0
CSCD
2
CNKI被引量
关联资源
相关文章
相关作者
相关机构